S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
Freshworks gets juiced on its AI customer engagement platform
All the trading advice you’ve ever received boils down to this (Ad)
3 tech outperformers adored by analysts
High short interest stocks: this popular trend is re-emerging
All the trading advice you’ve ever received boils down to this (Ad)
Boeing glides past series of setbacks on new flight path
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
All the trading advice you’ve ever received boils down to this (Ad)
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
Stock market today: World shares mostly higher after Wall Street hits 2023 peak
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
Freshworks gets juiced on its AI customer engagement platform
All the trading advice you’ve ever received boils down to this (Ad)
3 tech outperformers adored by analysts
High short interest stocks: this popular trend is re-emerging
All the trading advice you’ve ever received boils down to this (Ad)
Boeing glides past series of setbacks on new flight path
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
All the trading advice you’ve ever received boils down to this (Ad)
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
Stock market today: World shares mostly higher after Wall Street hits 2023 peak
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
Freshworks gets juiced on its AI customer engagement platform
All the trading advice you’ve ever received boils down to this (Ad)
3 tech outperformers adored by analysts
High short interest stocks: this popular trend is re-emerging
All the trading advice you’ve ever received boils down to this (Ad)
Boeing glides past series of setbacks on new flight path
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
All the trading advice you’ve ever received boils down to this (Ad)
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
Stock market today: World shares mostly higher after Wall Street hits 2023 peak
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
Freshworks gets juiced on its AI customer engagement platform
All the trading advice you’ve ever received boils down to this (Ad)
3 tech outperformers adored by analysts
High short interest stocks: this popular trend is re-emerging
All the trading advice you’ve ever received boils down to this (Ad)
Boeing glides past series of setbacks on new flight path
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
All the trading advice you’ve ever received boils down to this (Ad)
Biden goes into 2024 with the economy getting stronger, but voters feel horrible about it
Stock market today: World shares mostly higher after Wall Street hits 2023 peak

BriaCell Therapeutics (BCTX) Stock Price, News & Analysis

$4.72
-0.18 (-3.67%)
(As of 12/8/2023 08:56 PM ET)
Compare
Today's Range
$4.64
$4.97
50-Day Range
$3.79
$5.97
52-Week Range
$3.67
$8.10
Volume
79,200 shs
Average Volume
129,736 shs
Market Capitalization
$75.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.00

BriaCell Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
323.7% Upside
$20.00 Price Target
Short Interest
Bearish
7.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.14) to ($1.05) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

598th out of 942 stocks

Pharmaceutical Preparations Industry

275th out of 424 stocks


BCTX stock logo

About BriaCell Therapeutics Stock (NASDAQ:BCTX)

BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company, which engages in the development of immunotherapies for the treatment of cancer. Its technologies include Bria-IMT and Bria-OTS. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

BCTX Stock Price History

BCTX Stock News Headlines

BCTX: November 2023 SITC Poster
The Battery Metal Nobody Told You About
According to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy. Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium "the future of battery tech."
BriaCell Therapeutics Corp Ordinary Shares - New BCTX
BCTX: Year in Review
BriaCell Therapeutics Corp Ordinary Shares - New
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
BCTX: Pivotal Study Protocol Cleared
BCTX: Posters Galore at AACR
BCTX: 82% Survival Benefit
BCTX BriaCell Therapeutics Corp.
BCTX: Down in San Antone
See More Headlines
Receive BCTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/25/2023
Today
12/11/2023
Next Earnings (Estimated)
12/13/2023
Fiscal Year End
7/31/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BCTX
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.00
High Stock Price Target
$20.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+323.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-20,300,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.24) per share

Miscellaneous

Free Float
12,434,000
Market Cap
$75.44 million
Optionable
Not Optionable
Beta
1.34
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report














BCTX Stock Analysis - Frequently Asked Questions

Should I buy or sell BriaCell Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BriaCell Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BCTX shares.
View BCTX analyst ratings
or view top-rated stocks.

What is BriaCell Therapeutics' stock price target for 2024?

1 brokers have issued twelve-month price objectives for BriaCell Therapeutics' stock. Their BCTX share price targets range from $20.00 to $20.00. On average, they predict the company's stock price to reach $20.00 in the next year. This suggests a possible upside of 323.7% from the stock's current price.
View analysts price targets for BCTX
or view top-rated stocks among Wall Street analysts.

How have BCTX shares performed in 2023?

BriaCell Therapeutics' stock was trading at $4.37 on January 1st, 2023. Since then, BCTX stock has increased by 8.0% and is now trading at $4.72.
View the best growth stocks for 2023 here
.

When is BriaCell Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, December 13th 2023.
View our BCTX earnings forecast
.

How were BriaCell Therapeutics' earnings last quarter?

BriaCell Therapeutics Corp. (NASDAQ:BCTX) released its quarterly earnings data on Wednesday, October, 25th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.25.

When did BriaCell Therapeutics IPO?

(BCTX) raised $15 million in an initial public offering (IPO) on Wednesday, February 24th 2021. The company issued 3,300,000 shares at a price of $4.25-$5.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

Who are BriaCell Therapeutics' major shareholders?

BriaCell Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include K.J. Harrison & Partners Inc (0.41%), K2 Principal Fund L.P. (0.16%), Concord Wealth Partners (0.07%), Sabby Management LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of BriaCell Therapeutics?

Shares of BCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BCTX) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -